Search This Blog

Thursday, November 11, 2021

Coloplast goes for the throat

 The third-largest medtech acquisition of the year happened with little fanfare this week. Coloplast spent €2.2bn ($2.5bn) on Atos Medical, a maker of devices for tracheostomy and laryngectomy patients, knocking ICU Medical’s purchase of Smiths Group’s medical business into fourth place. The Sweden-based Atos occupies more than 80% of the laryngectomy market, according to Coloplast, with sales last year of SEK2.2bn ($253m). Coloplast, which had a difficult 2020 as the pandemic hit its hospital business, has recovered surprisingly well, with its stock up 23% year to date. Its sales are forecast to grow at a respectable annual rate of 8% to 2026, Evaluate Medtech data show; perhaps, with the inclusion of Atos’s technology, they will grow faster still. 

Top 5 medtech M&A of 2021
Announcement dateAcquirerTargetValue ($bn)Focus
Sep 1Baxter InternationalHill-Rom10.5General hospital & healthcare supply; healthcare IT
Jan 12SterisCantel Medical4.6Endoscopy; general & plastic surgery; nephrology
Nov 8Coloplast Atos Medical2.5Ear, nose & throat; general hospital & healthcare supply
Sep 8ICU MedicalSmiths Medical (subunit of Smiths Group)2.4Anaesthesia & respiratory; patient monitoring
Mar 12RocheGenmark Diagnostics1.8In vitro diagnostics
Note: excludes Spac deals. Source: Evaluate Medtech & company release. 

https://www.evaluate.com/vantage/articles/news/snippets/coloplast-goes-throat

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.